Argentarii’s Bristol-Myers Squibb BMY Stock Holding History

Argentarii’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,755	Closed	-$595K	–	158
2025 Q1	$595K	Buy	9,755 +5,361	+122%	+$312K	0.3%	82
2024 Q4	$249K	Buy	+4,394	New	+$246K	0.12%	131

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Argentarii's BMY Position: Q2 2025 in Review

Argentarii sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 9,755 shares — an estimated $595K sold.

Argentarii first reported a position in BMY in Q4 2024 and held it in 2 quarters. The position peaked at $595K in Q1 2025. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

Argentarii reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
Argentarii sold 9,755 Bristol-Myers Squibb shares in Q2 2025, an estimated $595K.
Argentarii first reported a position in Bristol-Myers Squibb in Q4 2024 and held it in 2 quarters.
Argentarii's Bristol-Myers Squibb position peaked at $595K in Q1 2025.
2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on Argentarii's 13F filing for Q2 2025, filed 14 Jul 2025.